Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Biomarkers predict response to nivolumab plus ipilimumab in metastatic colorectal cancer. Inflammation markers favor nivolumab alone, while tumor mutational burden and microsatellite instability favor combination therapy.
Area Of Science
- Oncology
- Immunotherapy
- Genomics
Background
- Nivolumab and ipilimumab show benefit in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
- Biomarker-driven treatment selection may optimize immunotherapy efficacy.
Purpose Of The Study
- To explore tissue biomarkers associated with nivolumab (alone or with ipilimumab) efficacy in previously treated MSI-H/dMMR mCRC.
- To investigate if inflammation or tumor antigenicity predicts response to different immunotherapy regimens.
Main Methods
- Exploratory biomarker analyses from the phase 2 CheckMate 142 study.
- Evaluation of gene expression signatures, tumor mutational burden, indel burden, and microsatellite instability.
Main Results
- Higher inflammation signatures correlated with better response and survival with nivolumab monotherapy.
- Higher tumor mutational burden, indel burden, and MSI correlated with better response and survival with nivolumab plus ipilimumab.
- These findings suggest tumor antigenicity may be key for combination therapy efficacy.
Conclusions
- Biomarker profiles may help differentiate optimal immunotherapy strategies for MSI-H/dMMR mCRC.
- Tumor antigenicity appears more critical than baseline inflammation for combination therapy.
- Further validation in larger randomized trials is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...